Huang Pei-Yu | Nasopharyngeal Carcinoma | Sun Yat-sen University Cancer Center-Sun Yat-sen University Cancer Center

Name: Huang Pei-Yu

Title: Associate Professor

Email: huangpy@sysucc.org.cn

Phone:

Profile

Dr. Pei-yu Huang has worked in the nasopharyngeal carcinoma(NPC) department of Sun Yat-sen University Cancer Center for more than ten years (as a resident doctor in 2002, as a attending doctor in 2005 and as a associate professor in 2014). He has finished more than 2, 000 nasopharyngeal biopsy and treated more than 1,000 NPC patients in the last ten years. Therefore, he has the full experiences of diagnosis of NPC and multidisciplinary treatment of NPC patients.Dr. Pei-yu Huang is a associate professor of nasopharyngeal carcinoma (NPC) department of Sun Yat-sen University Cancer Center. Dr. Huang obtained his Bachelor in Medicine (equivalent to MD in the US) and PhD at Sun Yat-sen University of Medical Sciences and Sun Yat-sen University, P. R. China in 2000 and 2009, respectively. He has been an active contributor to the field of clinical trials of multidisciplinary treatment of NPC, also he has unordinary interest in signaling pathway and target identifying study in NPC. Besides, Dr. Huang has published more than twenty research papers.

Interests

Clinical trials of multidisciplinary treatment of NPC & signaling pathway and target identifying study in NPC.

Education

Obtained Bachelor in Medicine (equivalent to MD in the US) and PhD at Sun Yat-sen University of Medical Sciences and Sun Yat-sen University, P. R. China in 2000 and 2009, respectively.

Publications

1. Huang PY, Wang CT, Cao KJ, Guo X, Guo L, Mo HY, Wen BX, Wu YS, Mai HQ, Hong MH *. Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: Findings from a randomised trial. Eur J Cancer. 2013 May;49(8):1923-31.

2. Huang PY, Cao KJ, Guo X, et al. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Oral Oncol. 2012 Oct; 48(10):1038-1044.

3. Huang PY, Li Y, Mai HQ, et al. Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy. Oral Oncol. 2012 Oct; 48(10): 964-968.

4. Wan XB, Fan XJ, Huang PY (Co-first author), et al. Aurora-A activation, correlated with hypoxia-inducible factor-1α, promotes radiochemoresistance and predicts poor outcome for nasopharyngeal carcinoma. Cancer Sci. 2012 Aug;103(8):1586-94.

5. Wu,X, Huang PY (Co-first author), Peng, PJ，Han F, Zhao C, Zhang L*. Long term follow up of a PhaseIII Study Comparing Radiotherapy with or without Weekly Oxaliplatin for Locoregionally Advanced Nasopharyngeal Carcinoma.Ann Oncol. 2013 Aug;24(8):2131-6.

6. Xue C, Huang Y, Huang PY(Co-first author), et al. Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol. 2013 Apr;24(4):1055-61.

7. Huang PY, Mai HQ, Luo DH, Induction-concurrent chemoradiotherapy versus induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngealcarcinoma.Ai Zheng(Chinese). 2009 Oct;28(10):1033-42.

8. Huang PY, Hong MH, Zhang X, et al. C-KIT overexpression and mutation in nasopharyngeal carcinoma cell lines and reactivity of Imatinib on these cell lines. Chin J Cancer(Chinese). 2010 Feb;29(2):131-5.

9. Huang PY, Wang B, Zhang X, et al. Expression and clinical significance of c-kit in nasopharyngeal carcinoma on tissue microarrary. Chinese Clinical Oncology (Chinese), 2009,14(2):97-101.

10. Huang PY, Zhang L, Zhang X, et al. C-KIT mutation exists in nasopharyngeal carcinoma. China Oncology (Chinese), 2009,19(4):266-269.

Updated by International Office, Sun Yat-sen University Cancer Center

Our Experts